Lobe Sciences (TSE:LOBE)
:LOBE
Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$29.83M
Enterprise ValueC$19.53M
Total Cash (Recent Filing)C$4.96M
Total Debt (Recent Filing)C$316.49K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,102,500
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Therapeutic FocusA specialized R&D focus on psychedelic-derived therapeutics and neurological disorders creates a clear, durable scientific niche. This concentrated pipeline and expertise support sustained product development efforts and potential regulatory pathways, reinforcing long-term strategic positioning within a distinct therapeutic area.
Modest Reported LeverageReported low absolute debt and a modest debt-to-equity ratio reduce near-term creditor pressure and interest burden. This balance-sheet profile provides some flexibility to fund operations or trials without immediate heavy debt servicing, lowering short-term insolvency risk compared with highly leveraged peers.
Evidence Of Positive Gross Margins HistoricallyPrior periods with meaningful gross profit imply the company can achieve positive unit economics once revenue is reestablished. That historical gross-profit evidence supports the sustainability of margins at scale and suggests operating losses largely reflect investment and scale-up rather than structurally unprofitable product economics.
Bears Say
No Revenue And Persistent LossesThe absence of revenue and sustained multi-period operating and net losses indicate the business is not yet operating at commercial scale. Persistent losses reduce internal funding capacity, necessitate external capital to continue development, and heighten execution risk for clinical programs and commercialization plans.
Deep Negative Operating Cash FlowConsistent, large negative operating and free cash flow point to ongoing cash burn and reliance on external financing. Limited internal cash generation constrains the company's ability to fund trials, R&D and working capital organically, increasing dilution or refinancing risk and complicating long-term operational planning.
Unstable Equity And Capital BaseHistorical negative equity and material swings in assets signal a fragile capital base that can restrict access to credit and strategic flexibility. Such instability increases the probability of financing strain, potential solvency scrutiny, and limits the company's ability to absorb setbacks without dilutive capital raises.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$29.83M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 51 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.636%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---